Drug substance manufacturing in Alnwick, UK
In 2021, Quotient Sciences acquired Arcinova, a UK contract development & manufacturing organization (CDMO).
Over the last several years, the facility expanded: a £6-million project was completed in 2022 to extend drug substance manufacturing. The facility features multi-purpose capacity of up to 14 GMP reactor streams with reactor volumes ranging from 5 liters up to 150 liters and deployment of both batch or continuous flow chemistry technologies.
In 2025, Quotient Sciences announced the reformation of the Arcinova brand, combining capabilities from Alnwick and Reading, UK. Learn about the services that we are proud to now offer through Arcinova.
